Vagus Nerve Stimulation (Human)(2 expert discussions analyzed)
What if a penny-sized implantable device could reduce inflammation as well as some biologic drugs — without suppressing the immune system? Vagus nerve stimulation (VNS) is showing trial-supported reductions in rheumatoid arthritis disease activity through a fundamentally different mechanism than drugs: activating the body's own anti-inflammatory reflex rather than blocking the immune system.
First synthesised Jun 9, 2026·Last reviewed Jun 9, 2026
What matters
Primary Topic Intent
Help readers understand what vagus nerve stimulation actually does, where the evidence currently stands for specific conditions (rheumatoid arthritis, Long COVID, Crohn's disease, depression, epilepsy), and what conversations to have with a specialist about candidacy for trials or established uses.
The vagus nerve carries signals from the brain to most internal organs, including signals that downregulate inflammatory responses. Vagus nerve stimulation (VNS) sends small electrical pulses to the vagus nerve to activate what researchers call the 'inflammatory reflex' — the neural pathway by which vagal activity reduces systemic inflammation. VNS is fundamentally different from immunosuppressive drugs: instead of blocking the immune system, it activates the body's own anti-inflammatory pathway. Two main delivery forms exist: implantable devices (about the size of a penny) placed under the skin near the neck, and non-invasive external devices that stimulate the vagus through the neck or ear.
VNS is established as standard care for two conditions: refractory epilepsy (FDA-approved since 1997) and treatment-resistant depression (FDA-approved since 2005). Both indications use implantable devices and have decades of clinical experience. The mechanism for these uses is partly anti-inflammatory and partly direct neural modulation; the precise contribution of each pathway continues to be investigated.
Recent controlled clinical trials in rheumatoid arthritis (RA) patients who have failed multiple standard therapies, including biologics, show that just one minute of daily VNS may produce meaningful reductions in disease activity. Dr. John Tesser describes the patient population as 'those who had failed everything we had to throw at them and now have something to try that doesn't suppress their immune system.' The approach is currently positioned as a last-line option for refractory patients, not a replacement for first- or second-line drug therapy. Surgical risks including possible vocal cord effects exist alongside long-term efficacy questions still under investigation.
A randomized controlled trial of VNS for Long COVID missed its primary endpoint as published in December 2025 (Long COVID Web webinar synthesis from Putrino and Nath). Secondary physiological data suggests higher doses or combination with antihistamines like famotidine may still help some patients with autonomic dysfunction. The broader framing emerging from this trial: Long COVID likely needs combination therapy more like cancer treatment than single-drug approaches like primary care. VNS may be one component of a multi-mechanism approach matched to specific Long COVID subtypes (autonomic, viral persistence, immune dysregulation) rather than a universal treatment.
VNS is in active study for Crohn's disease, multiple sclerosis, and Long COVID autonomic dysfunction. If results hold across diseases, bioelectronic medicine may emerge as an additional therapeutic category alongside drugs and surgery if current research trends continue. The shift is still in its early stages. Long-term comparative trials of VNS versus established biologics in RA, and confirmation of combination protocols in Long COVID, are the most important pending questions.
Best-supported action
Asking about VNS trial eligibility is the most consistently supported starting move, but where the conversation goes depends on which condition you have and what trade-offs you face. For refractory RA after multiple biologic failures, VNS is a last-line option with controlled trial support and surgical risks that may be acceptable given the alternative of continued immunosuppression. For Long COVID with autonomic symptoms, VNS as a stand-alone intervention missed its primary trial endpoint, but combination with famotidine may matter more than the device alone — and the right approach depends on your specific symptom subtype. For Crohn's disease or multiple sclerosis, the option is currently research-stage and trial enrollment may give earlier access than waiting for guideline incorporation. Getting this distinction wrong can mean either pursuing surgical implantation prematurely, or missing a real option that current rheumatology or post-COVID care does not raise.
Limits and unknowns
Understand where experts converge, where they differ, and what remains uncertain.
This does not prove that VNS works for all RA patients; controlled trials have focused on patients who failed multiple prior therapies, and the device may not benefit patients who respond well to standard biologics.
This does not prove that VNS is safer than established RA drugs in the long term; longer follow-up is needed to compare cumulative surgical-and-device risk against cumulative drug side-effect risk.
The Long COVID VNS trial as published missed its primary endpoint. Whether higher doses or combination protocols (such as VNS + famotidine) will work in confirmatory trials is unknown. This does not prove VNS cannot help Long COVID; only that the trial as designed did not meet its threshold.
Source coverage limitation: the two podcasts synthesized here cover RA and Long COVID. The established uses of VNS in refractory epilepsy and treatment-resistant depression are mentioned as context but are not deeply covered. A patient considering VNS for epilepsy or depression should consult neurology or psychiatry sources beyond this page.
Surgical risks including possible vocal cord effects, infection at the implant site, and device-related complications are real and should be discussed explicitly with the implanting surgical team before consenting to implantation.
Non-invasive external VNS devices (sold for home use, sometimes marketed for wellness) have a much weaker evidence base than implantable devices for medical indications. The synthesis here focuses on implantable VNS in clinical settings; external devices are a separate question that the two sources do not address in depth.
This does not mean you should change or stop any current medical treatment on your own.
Episodes
This topic is based on 2 expert episodes totalling 117 minutes of content.
Explore the full synthesis
Our editorial synthesis identified:
The full synthesis unlocks:
- Expert Deep Dive audio: the complete synthesis across all expert discussions
- Full ranked strategy list
- Emerging strategies worth watching
- Which approaches fit different situations
- Health models and cross-topic connections
- Doctor preparation and a printable summary